PTGER4
Prostaglandin E2 receptor EP4 subtype
As of the edition of 20 October 2026, PTGER4 (prostaglandin E2 receptor EP4 subtype, UniProt P35408) has 5 drugs tested at it and 5 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35408
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Cancer; Skin and connective tissue; Digestive system; Bones, joints and muscles; Nervous system; Nutrition and metabolism
- Registered trials of its drugs
- 53
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 3 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dinoprostone | Marketed | Phase 4 | none listed |
| Grapiprant | Stopped | Phase 2 | none listed |
| Vorbipiprant | Active | Phase 2 | none listed |
| Bgc-20-1531 free base | Stopped | Phase 2 | none listed |
| Rivenprost | Stopped | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Ikena Oncology | Route A |
| Boston Scientific | Route A |
The other 2 companies at PTGER4
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at PTGER4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.